KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Common Equity (2016 - 2025)

Historic Common Equity for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $1.6 billion.

  • Idexx Laboratories' Common Equity fell 351.46% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year decrease of 351.46%. This contributed to the annual value of $1.6 billion for FY2024, which is 746.25% up from last year.
  • Per Idexx Laboratories' latest filing, its Common Equity stood at $1.6 billion for Q3 2025, which was down 351.46% from $1.5 billion recorded in Q2 2025.
  • In the past 5 years, Idexx Laboratories' Common Equity ranged from a high of $1.6 billion in Q3 2024 and a low of $457.0 million during Q2 2022
  • Over the past 5 years, Idexx Laboratories' median Common Equity value was $1.1 billion (recorded in 2023), while the average stood at $1.1 billion.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 55099.72% in 2021, then tumbled by 3892.09% in 2022.
  • Quarter analysis of 5 years shows Idexx Laboratories' Common Equity stood at $690.0 million in 2021, then dropped by 11.78% to $608.7 million in 2022, then soared by 143.87% to $1.5 billion in 2023, then grew by 7.46% to $1.6 billion in 2024, then fell by 2.14% to $1.6 billion in 2025.
  • Its Common Equity was $1.6 billion in Q3 2025, compared to $1.5 billion in Q2 2025 and $1.4 billion in Q1 2025.